Experimental vaccine considered for early access

Mon 29 September 2014

An experimental vaccine for glioblastoma brain tumours has become the first in the UK to be designated a ‘Promising Innovative Medicine’ as part of the Government’s Early Access to Medicines scheme.

The scheme has been set up to provide patients who have exhausted all other treatment options with ground-breaking new medicines years before they would normally reach them.
Now that the experimental vaccine has been given ‘Promising Innovative Medicine’ status, the Medicines and Healthcare products Regulatory Agency (MHRA) can approve it for use by patients following a scientific assessment of the therapy.

Called DCVax-L, the vaccine works by using the body’s own immune system to recognise and attack cancer cells.


Source: The Brain Tumour Charity 18/09/14